Sionna Therapeutics (NASDAQ:SION) Reaches New 12-Month Low Following Weak Earnings

Sionna Therapeutics, Inc. (NASDAQ:SION)’s share price reached a new 52-week low on Friday following a dissappointing earnings announcement. The company traded as low as $12.46 and last traded at $13.04, with a volume of 30317 shares trading hands. The stock had previously closed at $13.88.

The company reported ($3.38) earnings per share for the quarter, missing the consensus estimate of ($2.68) by ($0.70).

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Stifel Nicolaus began coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating and a $32.00 price objective on the stock. Guggenheim began coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating and a $45.00 target price for the company. Finally, TD Cowen began coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating for the company.

Sionna Therapeutics Stock Down 6.1 %

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.